Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.33 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4147433 | 0.83 | — | — | |
| SCHEMBL4160100 | 0.80 | GRIN2D (0.33) | — | |
| SCHEMBL4149894 | 0.77 | ALOX15 (0.43) | — | |
| SCHEMBL4162429 | 0.77 | SLC7A5 (0.37) | SLC7A5 | |
| SCHEMBL2541315 | 0.76 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL66234 | 0.76 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL66233 | 0.76 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL7318373 | 0.76 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL7318378 | 0.76 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL4153755 | 0.76 | MARS1 (0.33) | RNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099307-A1 | Inverse solid phase peptide synthesis with additional capping step | ACTIVOTEC SPP LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20080242836-A1 | Convergent Solid Phase Peptide Synthesis By Reaction Of Two Fragments Bound To Solid Support | UNIVERSITY OF SOUTHAMPTON (GB) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099307-A1 | Inverse solid phase peptide synthesis with additional capping step | RNGTT, CPSF7, CPSF1 | SLC7A5 1663/4885SLC1A3 3264/4885SLC1A2 4168/4885 |
| US-20080242836-A1 | Convergent Solid Phase Peptide Synthesis By Reaction Of Two Fragments Bound To Solid Support | CPSF1, CPSF7, MAX | SLC7A5 1096/4885SLC1A3 1499/4885SLC1A2 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.